Novavax COVID-19 Vaccine Candidate 96.4% Effective In U.K. Trial, Company Says
Novavax announced Thursday its vaccine candidate proved to be 96.4% effective against mild, moderate and severe cases of COVID-19 in a Phase 3 trial in the United Kingdom.